New palliative treatment for advanced prostate cancer
According to the American Cancer Society, one in six American men will develop prostate cancer in his lifetime. Now there is a new treatment for the disease that is administered using a unique technology.
Atrix Laboratories says Eligard 7.5mg, is a new hormone therapy which combines a well-established drug called leuprolide acetate with a unique delivery technology that allows the drug to be slowly released into the body over a thirty-day period.
The drug lowers testosterone levels. thereby inhibiting growth of the cancer. Dr. Franklin Chu has conducted research on Eligard and has prescribed it for many of his patients.
Eligard is given with a very small needle, directly into the skin, as opposed to using a very large pore needle under the skin, or using a deep intramuscular injection.
Atrix contact: Elana Bodner, 212-812-7037
Posted: June 2002